← Special Reports
NeurologyAlzheimer Disease

Alzheimer Disease-Modifying Therapy: From Approval to Real-World Practice

Lecanemab and donanemab are approved. The harder question is who gets them and how

SR-2026-009
EditorMara Voss
CopywritersEditorial Team
Coming Soon

Alzheimer Disease-Modifying Therapy: From Approval to Real-World Practice

Lecanemab and donanemab are approved. The harder question is who gets them and how

Why We Are Covering This

Two disease-modifying Alzheimer therapies are now in broad rollout, but real-world implementation is the challenge that matters most. AAN 2026 data on ARIA risk and ApoE4 screening is reshaping who qualifies and who does not.

What to Expect

You will leave knowing how to build an amyloid screening pathway, which patients are excluded by genetic or imaging criteria, and how to monitor for ARIA safely in a community neurology practice.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first
The Life Science Feed
thelifesciencefeed.com · Special Report
SR-2026-00907/26

Related Articles

Dopamine Agonists: A Fading Role in Parkinson's Treatment?Parkinson Disease

Dopamine Agonists: A Fading Role in Parkinson's Treatment?

Dopamine agonists, once a cornerstone for Parkinson's disease, face increasing scrutiny due to neuropsychiatric side effects and limited long-term motor benefits.

9 min readGet the full story
Eptinezumab Improves Cognitive Symptoms in Migraine PatientsMigraine Disorders

Eptinezumab Improves Cognitive Symptoms in Migraine Patients

Eptinezumab significantly reduced cognitive symptoms in patients with migraine, offering a new dimension of relief beyond headache frequency.

13 min readGet the full story
Migraine Linked to Increased Vascular Dementia Odds in Observational DataMigraine Disorders

Migraine Linked to Increased Vascular Dementia Odds in Observational Data

Observational studies indicate a consistent association between a history of migraine and elevated odds for developing vascular dementia later in life.

11 min readGet the full story
Huntington's Disease Therapy Faces Regulatory Setbacks, Clinical ImpactAmyotrophic Lateral Sclerosis

Huntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact

A novel investigational therapy for Huntington's disease has encountered significant regulatory hurdles, prompting re-evaluation of its clinical development pathway.

10 min readGet the full story
    0:00 / 0:00